Navigation Links
Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
Date:8/19/2007

International Clinical Data to be Presented at the 58th Annual Meeting of

the American Association for the Study of Liver Diseases (AASLD)

TAMPA, Fla., Aug. 15 /PRNewswire/ -- Romark Laboratories announced that it has initiated a phase II clinical trial of Alinia(R) (nitazoxanide) for treating chronic hepatitis C in the United States.

The clinical trial is designed to evaluate the effectiveness and safety of Alinia tablets administered in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) in 60 patients with chronic hepatitis C genotype 1 who have failed to respond to standard therapy (peginterferon and ribavirin). Pegasys and Copegus are being provided under a collaborative agreement between Romark and F. Hoffmann-La Roche Ltd.

"We are excited to be participating in this clinical trial," said David Nelson, M.D., Associate Professor of Medicine, Medical Director of Liver Transplantation, and Chief of the Hepatobiliary Disease Section at the University of Florida. "There is a critical need for new therapies for patients with hepatitis C, particularly those who have already failed existing therapies."

The company also announced that interim data from an international clinical trial in patients with chronic hepatitis C will be communicated at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in early November 2007.

"Initiation of the US study and communication of our international data represent important milestones for our development program," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark who invented nitazoxanide and is leading its clinical development. "We are enthusiastic about the results to be presented at the upcoming AASLD meeting and the opportunity to develop an important new treatment for patients suffering from chronic hepatitis C."

The company's STEALTH C (Studies to Evaluate Alinia for Treatment
'/>"/>

SOURCE Romark Laboratories, L.C.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. BioRobot MDx standardize your automated protocols in clinical laboratories
2. What patients want: A story of choice, clinical trials & evidence-based medicine
3. ZyStor seeks to raise $15M for clinical trials
4. Prodesse begins clinical trials for flu virus detection
5. ConjuGon raises $3.3 million to fund clinical trials
6. Cancer-fighting agent heads for clinical trials
7. Quintessence cancer treatment chosen for clinical studies
8. Third Wave reports clinical growth, continued loss
9. Childrens expanding use of Sunrise Clinical Manager
10. Life-sciences conference to feature novel research with clinical potential
11. $14 million grant to drive clinical research at UW
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... April 28, 2015 IMS is ... bring it to the web and provide greater ... user friendly reporting metrics increase data warehouse’s utility; ... convenient recall and access “on-the-go” makes data analysis ... using client feedback to assist in repository analytics ...
(Date:4/28/2015)... Reproductive endocrinologist Dr. Kaylen Silverberg , ... battling infertility in this country, testified on behalf of ... first state in the nation to consider creating a clearinghouse ... who desire to receive them. , Infertility affects over 7.3 ... is one of the few medical diseases that is curable, ...
(Date:4/27/2015)... 27, 2015 Dr. Robert Hanzlik, whose ... toxicity carries implications for advancing the creation of safer ... National University , the second-largest private, nonprofit university ... Hanzlik, a professor at the University of Kansas School ... design, starts at 5 p.m. and takes place at ...
(Date:4/27/2015)... Kan. , April 27, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today provided commentary on clinical study ... during a poster session at the American Association ... ADXS31-164 is a novel Lm -LLO ...
Breaking Biology Technology:Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 2Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 3Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2
... TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) ... the Southern District of New York dismissed proceedings filed ... ("Axonyx") against Axonyx and several of Axonyx,s former directors ... plaintiffs alleged that the defendants made misleading statements related ...
... Enterprises, Inc. (BME), a rapidly growing medical device company ... implants, announced today that it has appointed Keith M. ... BME specializes in nitinol implants that contract and compress ... bone union. The O rthopaedic S ...
... Cell Trial to Show Dose-related Significant Improvement in Perfusion ... Amorcyte, Inc. (Amorcyte) today announced data from its Phase ... for the treatment of damaged heart muscle following acute ... cell dose and biologic effect. This is the first ...
Cached Biology Technology:Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed 2BioMedical Enterprises, Inc. (BME) Announces the Appointment of Keith M. Peeples as Vice President, Sales and Marketing 2Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 2Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 3Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 4
(Date:3/31/2015)... , March 31, 2015   Guidepoint , ... launch of the Post-Surgical Pain Management TRACKER, part of ... tracking usage trends in the medical device and therapeutics ... to data including treatment volumes, market share, and adoption ... pain associated with joint surgery. The Post-Surgical ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... A component of DNA that can both stimulate ... may hold hope for treating cancer and infection, Medical ... of CpG increase inflammation, part of the body,s way ... increasing expression of the enzyme indoleamine 2,3 dioxygenase, or ...
... A new study by researchers at Princeton University,s Woodrow ... that global climate change may lead to the retreat ... States, which could create unprecedented ecological restoration opportunities across ... time, global warming may enable other invasive plants to ...
... a surprising link between brain iron levels and ... from autism to major depression., Appearing in the ... this week, the study by Randy Blakely, ... a powerful in silico approach for discovering novel ...
Cached Biology News:DNA component can stimulate and suppress the immune response 2Climate change's impact on invasive plants in Western US may create restoration opportunities 2Climate change's impact on invasive plants in Western US may create restoration opportunities 3Climate change's impact on invasive plants in Western US may create restoration opportunities 4Researchers iron out new role for serotonin 2
...
... a-Amylase is an enzyme that ... mixture of maltose, maltotriose, and dextrins. ... of the human body is of,clinical ... states including,pancreatitis and diabetes; plant and ...
... The Jouan MSC series of Class ... working conditions and certification to the ... regulation ensures that the cabinets cannot ... conditions. Natural lighting, low noise and ...
... FL is equipped with ... measurement technologies that complement ... advanced features of Fluoroskan ... Fluoroskan Ascent FL provides ...
Biology Products: